Trial Profile
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Difelikefalin (Primary)
- Indications Pruritus
- Focus Registrational; Therapeutic Use
- Acronyms KALM-1
- Sponsors Cara Therapeutics
- 15 Nov 2023 Results of pooled dataset from KALM-1 and KALM-2 and NCT03998163 , evaluating whether itch reduction in CKD-aP improved sleep quality, published in the Nephrology Dialysis Transplantation
- 18 May 2023 According to Vifor Pharma media release, based on the data from KALM-1, KALM-2 as well as supportive data from an additional 32 clinical studies, England National Institute for Health and Care Excellence (NICE) has recommended Kapruvia for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on haemodialysis.
- 19 Aug 2022 According to a Cara Therapeutics media release, based on the data from KALM-1, KALM-2 as well as supportive data from an additional 32 clinical studies, the company received approval for Kapruvia from the Swiss Agency for Therapeutic Products (Swissmedic).